Mutations in FAT1, a gene of Hippo pathway, were associated with higher durable clinical benefit and significantly improved survival outcomes than wild‐type NSCLC patients, same results were also confirmed in melanoma patients and a pan‐cancer cohort.40, 41, 42. The gene discussed is FAT1; the disease is non-small cell lung carcinoma.